U.S. stocks closed rallied on Friday, with the Nasdaq Composite (COMP:IND) securing another back-to-back record, even as ...

Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

Pfizer (PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 revenue guidance of $61 billion to ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

As you can see, life has been very difficult for me. I am 30 years old, yet I look like a seven-year-old girl. I can't walk for a distance; and I can't afford to miss a step and fall down because the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...